OLMA News and Press, Olema Pharmaceuticals Inc. From 04/18/22

SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...

Gainers: Sera Prognostics (SERA) +10%. Harte-Hanks  (HHS) +7%. Precigen (PGEN) +5%. Greenidge Generation Holdings  (GREE) +5%. IGM Biosciences (IGMS) +5%. Losers: Connect Biopharma Holdings Limited (CNTB) -17%. Arhaus (ARHS) -5%. Fluent (FLNT) -5%. Marinus Pharmaceuticals ...

SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women&#...

Presented Phase 1a proof-of-concept data for OP-1250 in metastatic, ER+ / HER2- breast cancer, with demonstrated attractive pharmacokinetics, favorable tolerability and encouraging anti-tumor activity in a heavily pretreated patient population Enrollment in Phase 1b dose expan...

SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at t...

Olema Pharmaceuticals (NASDAQ:OLMA) granted stock options to two new employees to buy a total 270K common shares under the company's 2022 Inducement Plan. The company's new Chief Medical Officer Naseem Zojwalla was granted an option to buy 250K shares. While an option to purchase 20K sha...

SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of t...

• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela Klein, M.D., will become a senior advisor and member of Olema ...

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at t...

Energy Focus (NASDAQ:EFOI) +52% launches nUVo virus-targeted UVC air disinfectors to public. Lexaria Bioscience (NASDAQ:LEXX) +25% dehydraTECHTM-CBD reduces arterial stiffness, results confirmed in human clinical study HYPER-H21-2. Dare Bioscience (NASDAQ:DARE) +23% announces F...